Related Experiment Video
Updated: Oct 21, 2025

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Upper Extremity Deep Vein Thrombosis and Asymptomatic Vein Occlusion in Patients With Transvenous Leads: A Systematic
Daniël Duijzer1, Maria A de Winter2, Mathilde Nijkeuter2
1Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, Netherlands.
Insights
Transvenous leads increase the risk of upper extremity deep vein thrombosis (UEDVT), occurring years after implantation. Asymptomatic vein occlusion is also common, complicating future lead procedures.
Area of Science:
- Cardiology
- Vascular Medicine
- Medical Device Research
Background:
- Transvenous leads for cardiac device therapy are associated with venous thromboembolism risk.
- Systematic epidemiological data on these complications, specifically upper extremity deep vein thrombosis (UEDVT) and asymptomatic vein occlusion, are lacking.
Approach:
- A systematic literature search of PubMed, EMBASE, and Cochrane Library was conducted up to March 31, 2020.
- Pooled estimates for the incidence of symptomatic UEDVT and prevalence of asymptomatic vein occlusion were calculated from identified studies.
- Meta-regression was used to explore associations between lead number and UEDVT risk.
Key Points:
- The pooled incidence of symptomatic UEDVT was 0.9 per 100 patient-years, with high heterogeneity and limited low-risk-of-bias studies.
- The pooled prevalence of asymptomatic upper extremity vein occlusion was 8.6%, also with significant heterogeneity.
- Increased number of leads was associated with a higher risk of UEDVT.
Conclusions:
- Transvenous leads are a significant risk factor for symptomatic UEDVT, which can manifest years post-implantation.
- Existing research on UEDVT following lead implantation is largely of poor quality, necessitating high-quality prospective studies.
- A substantial proportion of patients exhibit asymptomatic vein occlusion, potentially complicating future lead interventions.
Abstract:
Aims: The presence of transvenous leads for cardiac device therapy may increase the risk of venous thromboembolisms. The epidemiology of these complications has not yet been determined systematically. Therefore, this study aims to determine (I) the incidence of symptomatic upper extremity deep vein thrombosis (UEDVT) and (II) the prevalence of asymptomatic upper extremity vein occlusion in patients with transvenous leads, both after the initial 2 months following lead implantation. Methods: PubMed, EMBASE, and Cochrane Library were searched until March 31, 2020 to identify studies reporting incidence of UEDVT and prevalence of asymptomatic vein occlusion after the initial 2 months after implantation in adult patients with transvenous leads. Incidence per 100 patient years of follow-up (PY) and proportions (%) were calculated to derive pooled estimates of incidence and prevalence. Results: Search and selection yielded 20 and 24 studies reporting on UEDVT and asymptomatic vein occlusion, respectively. The overall pooled incidence of UEDVT was 0.9 (95% CI 0.5-1.4) per 100PY after 2 months after lead implantation. High statistical heterogeneity was present among studies (I2 = 82.4%; P = < 0.001) and only three studies considered to be at low risk of bias. The overall pooled prevalence of asymptomatic upper extremity vein occlusion was 8.6% (95% CI 6.0-11.5) with high heterogeneity (I2 = 81.4%; P = <0.001). Meta-regression analysis showed more leads to be associated with a higher risk of UEDVT. Conclusion: Transvenous leads are an important risk factor for symptomatic UEDVT, which may occur up to multiple years after initial lead implantation. Existing data on UEDVT after lead implantation is mostly of poor quality, which emphasizes the need for high quality prospective research. Asymptomatic vein occlusion is present in a substantial proportion of patients and may complicate any future lead addition. Clinical Trial Registration: (URL: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020178136, Identifier: PROSPERO 2020 CRD42020178136).
More Related Videos
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Assessment of the Cardiovascular System III: Palpation
Jugular Venous Pressure (JVP) Measurement
Position the patient at a thirty- to forty-five-degree angle or in a semi-fowler's position. Look for the highest point of pulsation in the internal jugular vein and measure the vertical distance to the angle of Loius or sternal angle. A normal JVP is 3-4 cm above...

